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Objectives. We compared the effects of bisoprolol on transient 
myocardial ischemia with those of nifedipine in patients with 
chronic stable angina. 
Background. Both beta-adrenergic blocking agents and calcium 
antagonists reduce transient ischemic episodes, but comparisons 
of these agents have been made in only a few larger studies. 
Methods. The Total Ischemic Burden Bisoprolol Study (TIBBS) 
was a randomized ouble-blind controlled study with two parallel 
groups; 330 patients from 30 centers in seven European countries 
with stable angina pectoris, a positive xercise test and more than 
two transient ischemic episodes during 48 h of Holter monitoring 
(central evaluation) were included. Of these patients 161 were 
randomized to receive bisoprolol and 169 to receive nifedipine 
slow release. There were two treatment phases of 4 weeks each, 
with 48.h Holter monitoring after each phase. During phase 1, 
patients received either 10 mg of bisoprolol daily or 2 x 20 mg of 
nifedipine slow release. During phase 2, they received either 20 mg 
of bisoproloi daily or 2 x 40 mg of nifedipine slow release. 
Results. In phase 1 of the trial, 4 weeks of bisoproiol therapy 
(10 mg daily) reduced the mean [-+SD] number of transient 
ischemic episodes from 8.1 -+ 0.6 to 3.2 -+ 0.4/48 h. Nifedipine (2 x 
20 mg) reduced transient ischemic episodes from 83 ± 0.5 to 
5.9 -+ 0.4/48 h. Total duration of ischemia was reduced from 
99.3 -+ 10.1 to 31.9 -+ 5.5 rain/48 h with bisoprolol and from 101 _+ 9.1 
to 72.6 _+ 8.1 rain/48 h with nifedipine. Reductions were statistically 
significant for both drugs; the difference between bisoprolol and 
nifedipine was also significant (p < 0.0001). Bisoprolol reduced the 
heart rate at onset of episodes by 13.7 + 1.4 beats/rain from a 
baseline value of 99.5 ± 1.2 beats/min (p < 0.001). Heart rate was 
unchanged with nifedipine. Bisoprolol had significantly higher re- 
sponder rates than nifedipine. Doubling of the dose in phase 2 of the 
trial had small additive effects. Only bisoprolol showed a marked 
circadian effect by reducing the morning peak of transient ischemic 
episodes (by 68% at peak time, 8:00 to 8:59 AM). 
Conclusions. Both bisoprolol and nifedipine reduced the num- 
ber and duration of transient ischemic episodes in patients with 
chronic stable angina. Bisoprolol was significantly more effective 
than nifedipine in both doses tested and reduced the morning 
peak of ischemic activity. 
(J Am Coil Cardiol 1995;25:231- 8) 
Transient, predominantly silent, myocardial ischemia may de- 
serve treatment because of its prognostic implications (1-9). 
Beta-adrenergic blocking agents and calcium antagonists are 
prime candidates in the optimal treatment of transient isch- 
emia by improving the load conditions or the oxygen supply of 
the heart, or both (10). Several smaller studies (11-14) have 
addressed the etficacy of beta-blockers or calcium antagonists 
on transient ischemia. The purpose of the Total Ischemic 
Burden Bisoprolol Study (TIBBS) was to study the effect of 
bisoprolol, a cardioselective, 24-h active beta-blocker (15), on 
the number and duration of transient ischemic episodes com- 
pared with nifedipine, a calcium antagonist previously shown 
to be effective in transient ischemia (16,17). 
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Methods  
Study design. TIBBS was a randomized multicenter 
double-blind controlled study with two parallel groups. A 
placebo prephase of 10 days was followed by two treatment 
phases of 4 weeks each. Treatment during phase 1 was either 
with 10 mg of bisoprolol daily or 20 mg of nifedipine slow 
release twice a day. Treatment during phase 2 was double the 
dose of phase 1 for each group, that is, 20 mg of bisoprolol 
daily or 40 mg of nifedipine slow release twice a day. 
Sample size determination. We aimed for a power of 90% 
for detection of a difference between the groups of at least 
0.45 SD (alpha 5% two-tailed). This means that a difference of 
three episodes/48 h should be detectable. Therefore, the 
sample size determination was 100 patients/treatment group 
who should be evaluable with respect o number and duration 
of transient ischemic episodes. 
Patient selection. In 30 European centers (see Appendix 
for participating institutions and personnel), ambulatory pa- 
tients were recruited for the placebo prephase if they fulfilled 
the following inclusion criteria: history of typical stable angina 
pectoris and positive exercise tolerance test with ST segment 
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depression using a modified Bruce protocol on a treadmill or 
incremental work load of 25 W every 2 rain on a bicycle. For 
women, the presence of coronary artery disease had to be 
further documented bya definite history of myocardial infarc- 
tion, positive findings on the coronary angiogram with >70% 
stenosis in a major vessel or positive findings on exercise 
thallium scintigraphy. For men these additional diagnostic 
criteria were desirable but not mandatory. During the placebo 
prephase, the patients underwent 48-h ambulatory monitoring 
and were enrolled for randomized active treatment when they 
had at least two episodes of transient myocardial ischemia. 
Patients were excluded if they met one or more of the 
following exclusion criteria: unstable angina pectoris, myocar- 
dial infarction within the past 3 months, bradycardia with <50 
beats/rain during the daytime, significant first-degree atrioven- 
tricular (AV) block (PQ > 0.24 s), second- or third-degree AV 
block, hypotension with systolic blood pressure <100 mm Hg 
or suspected poor compliance. 
The following drugs were not given during the study: 
long-acting nitrates, beta-blockers (except he study medica- 
tion), afterload-reducing agents, including calcium channel 
blockers and angiotensin-converting e zyme inhibitors (except 
the study medication), alphal-adrenoceptor blockers and beta z- 
stimulants, tricyclic antidepressants or drugs known to influence 
ST segments ( uch as digitalis and antiarrhythmic agents). 
Study protocol. If a patient met the inclusion criteria, he or 
she entered the 10-day placebo prephase and performed the 
qualifying exercise tolerance test on day -10. At the same time 
a physical examination and chemical aboratory tests were 
performed. From day -6 to day -4, the 48-h ambulatory 
electrocardiographic (ECG) monitoring was done. Express 
delivery of the tapes to the central aboratory, immediate 
evaluation and communication f the results by telephone or 
fax ensured the inclusion of suitable patients into the random- 
ized treatment phases by day 0. At the end of treatment phase 
1 after 4 weeks and at the end of treatment phase 2 after 8 
weeks, 48-h Holter recordings were repeated, together with a 
check on anginal attacks, adverse vents and a tablet count. 
Ambulatory ECG monitoring. Two consecutive 24-h re- 
cordings were performed uring the placebo prephase and at 
the end of each treatment phase using Oxford Medilog MR45 
recorders and leads CM 5 and modified aVF. This is a combi- 
nation device incorporating conventional recording of the 
ECG as well as microprocessor-controlled on-line processing 
of the data for arrhythmia nd ST segment analysis (18). 
Accurate identification of QRS trigger, beat configuration and 
noise rejection is performed uring the recording. On noise- 
free beats belonging to a normal beat family, the recorder 
performs aseries of ST segment level and slope measurements 
directly from the patient leads, thus avoiding compromise of 
measurement accuracy by frequency response limitation or 
phase distortion common on tape-recorded ECGs. Verifica- 
tion of the data is possible by referring to the original, analog 
ECG. To ensure consistent evaluation, all tapes were read 
centrally and in a blinded manner in a core laboratory in 
London (J.A.D.) (see Appendix) using an Oxford Medilog 
Excel Analysis System. Each report was overread and reviewed 
(J.A.D.). 
The criteria for an ischemic episode were ->1 mm of 
horizontal or downsloping ST segment depression lasting 
__-1 rain and separated from another episode by ->1 rain. The 
maximal depth of the ST segment depression during each 
episode was noted to allow the calculation of an index of ST 
segment depression (mm) times duration (min) as the "total 
ischemic burden." Time and heart rate at the beginning of an 
episode of ischemia were documented. 
Tape results were accepted for further analysis only if 
->75% of the recorded 48 h were of technically acceptable 
quality. 
Statistical analysis. All data from the case report forms 
and the central Holter tape evaluation were continuously 
entered into a central data base. The randomization plan was 
not disclosed before all the data had been checked for plausi- 
bility and any necessary corrections had been carried out. The 
number and duration of ischemic episodes and the total 
ischemic burden as the difference from baseline were defined 
as primary target variables of efficacy. Results are presented as 
mean value _+ SEM. Differences from baseline values were 
checked for significance considering the 95% confidence limits. 
If the confidence interval does not include zero, the mean 
baseline difference was regarded as significantly different from 
zero. The efficacy variables were compared between the two 
treatment groups by the Wilcoxon rank-sum test. Comparisons 
within each group between the 4- and 8-week measurements 
were performed by the Wilcoxon signed-rank test. Responder 
rates were analyzed using the Fisher exact test. Significance 
level was alpha 5%, two-tailed. 
Results  
Study patients. From April 1991 to February 1993, 631 
patients fulfilled the inclusion criteria and had a positive result 
on the exercise ECG. Of these, 330 had two or more transient 
episodes of ischemia during 48-h ambulatory ECG monitoring 
and thus could be randomized to receive bisoprolol (161 
patients) or nifedipine (169 patients). The baseline character- 
istics of the randomized patients are shown in Table 1. There 
were no significant differences in gender, age, smoking history 
or other baseline values. 
Of the patients who started randomized treatment, there 
were 10 dropouts in the bisoprolol group and 17 in the 
nifedipine group, mostly because of adverse drug reactions 
(described later). Data had to be excluded from analysis 
because of ineligible tapes or protocol violations for 18 pa- 
tients in the bisoprolol group and 17 in the nifedipine group. 
Thus, for phase 1 of the randomized treatments there were 133 
patients with eligible tapes in the bisoprolol group and 135 in 
the nifedipine group. For phase 2 of the randomized treat- 
ment, weeks 5 to 8 on the double dose, there were 17 dropouts 
and 16 data exclusions in the bisoprolol group and 12 dropouts 
and 18 exclusions in the nifedipine group. Patients with eligible 
tapes for phase 2 included 118 with bisoprolol and 122 with 
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Table 1. Baseline Characteristics of Randomized Study Patients 
Bisoprolol Nifedipine Slow Release 
(n = 161) (n = 169) p Value 
Male/female 134/27 146/23 0.45 
Smoker and ex-smoker (%) 57.2 62.2 0.31 
Age (yr) 57.6 (38-77) 57.3 (32-78) 0.75 
History of angina (mo) 24.8 (1-256) 20.5 (2-195) 0.50 
Positive history of myocardial infarction 44 53 0.47 
Weight (kg) 77.2 ± 9.3 75.7 -- 9.8 0.16 
SBP (ram Hg) 139.9 + 16.2 140.0 _+ 18.9 0.92 
HR (beats/rain) 74.2 ± 10.6 74.0 + 10.3 0.85 
ETI" 
Maximal rate-pressure product 23,684 _+ 5,320 24,147 _+ 5,402 0.44 
(ram Hg x beats/rain) 
Maximal ST segment depression (mV) 0.22 +_ 0.10 0.22 _+ 0.09 0.80 
Data presented are mean value ± SD, median value (range) or number of patients. ETT = exercise tolerance t st; 
HR - heart rate; SBP = systolic blood pressure. 
nifedipine (patients with protocol violations or ineligible tapes 
at the end of phase 1 entered phase 2 of the trial in the normal 
way). In the bisoprolol group there were 111 patients (nifedi- 
pine slow release, 112 patients) with eligible tapes in both 
phase 1 and phase 2 of the trial. 
Treatment effects on ambulatory ischemia. Table 2 pre- 
sents an overview of the results obtained with ambulatory ECG 
monitoring. Number and duration of the ischemic episodes as 
well as the total ischemic burden showed a marked and 
statistically significant reduction with both antianginal drugs in 
the low dosages (confidence intervals do not include zero). All 
reductions were significantly greater with bisoprolol than with 
nifedipine (p < 0.0001); the effects of bisoprolol were about 
twice those of nifedipine. Heart rate at onset of ischemic 
episodes was 99.5 _+ 1.17 beats/rain in the bisoprolol group and 
101.2 _+ 1.03 beats/rain in the nifedipine group during the 
placebo prephase. At the end of the low-dose phase, 54 
patients in the bisoprolol group and 20 in the nifedipine group 
had no ischemic episodes. These patients were not included in 
the analysis of treatment effects on heart rate at the onset of 
ischemic episodes. Bisoprolol treatment resulted in a signifi- 
cant reduction in heart rate of 13.7 _+ 1.39 beats/rain, whereas 
with nifedipine a small but not significant increase of 1.4 _+ 
1.08 beats/rain was observed (p -- 0.0001, bisoprolol vs. 
nifedipine). 
The additional effects of the double dose of bisoprolol and 
nifedipine are summarized in Table 3. These effects are small 
and significant only for bisoprolol, with a further reduction in 
the number of ischemic episodes and mean heart rate at the 
onset of ischemic episodes. 
In Figure 1 the time course of the variables from baseline to 
high dose is presented for those patients with a valid 48-h 
Holter tape at baseline and at the end of the low and high dose 
treatment phases. 
Treatment effects on angina pectoris. The effects of both 
treatments on the number of angina attacks per week are 
Table 2. Effects of Low Doses in 133 Patients Taking Bisoprolol and 135 Patients Taking Nifedipine 
Baseline Low Dose Mean Change Median p Value 
(,mean +_ SEM) (mean ± SEM) (mean [95% confidence limit]) Change (bisoprolol vs. nifedipine) 
No. of episodes/48 h 
Bisoprolol 8.1 ÷ 0.56 3.2 ± 0.41 -4.9 (-5.8,-4.0)* -4.0 0.0001 
Nifedipine 8.3 +_ 0.50 5.9 ± 0.43 -2.5 (-4.3,-1.5)* -2.0 
Total duration of episodes (min/48 h) 
Bisoprolol 99,3 ± 10.13 31.9 ± 5.45 -67.4 (-84.0,-50.7)* -39.0 0.0001 
Nifedipine 101,0 +_ 9.10 72.6 ± 8.05 - 28.4 (-45.9,- 10.9)* - 12.0 
Total ischemic burden (ST segment 
depression [mini x episode 
duration [min]) 
Bisoprolol 193.7 _+ 27.14 58.9 ± 11.66 - 134.8 ( -  178.7,-90.9)* -46.0 0.0030 
Nifedipine 194.7 _+ 23.83 117.0 _+ 16.72 77.8 (-121.5,-34.0)* -23.0 
Mean HR before ST segment 
depression (beats/rain) 
Bisoprolol 99.5 ± 1.17 84.0 ~ 1.54t - 13.7 (-  16.5,- 11.0)*t - 14.2 0.0001 
Nifedipine 101.2 ± 1.03 102.7 ± 1.17~ +l.4 (-0.8, 3.5)t +1.4 
*Significant reduction; confidence limits do not include zero. ~79 patients in the bisoprolol group and 115 patients in the nifedipine group at the end of phase 1 
(only patients with ischemic episodes). HR = heart rate. 
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Table 3. Additional Effects of Double Dose of Bisoprolol and Nifedipine 
End Phase 1: Low Dose End Phase 2: High Dose Mean Change Median p Value 
No. of Pts (mean _+ SEM) (mean ,+ SEM) (mean [95% confidence limits]) Change (low dose vs. high dose) 
No. of episodes/48 h 
Bisoprolol 111 3.3 + 0.45 2.6 _+ 0.42 -0.7 (-1.4, 0.0) 0.0 0.030 
Nifedipine 112 6.1 +_ 0.48 5.7 - 0.56 -0.4 (-1.3, 0.4) 0.0 0.296 
Total duration of episodes 
(min/48 h) 
Bisoprolol 111 32.3 _+ 6.10 27.6 _+ 6.21 -4.7 (-14.0, 4.7) 0.0 0.141 
Nifedipine 112 75.5 _+ 8.99 69.7 ,+ 9.42 -5.8 (-19.2, 7.6) -5.0 0.140 
Total ischemic burden 
(ST segment depression 
[mm] x episode 
duration [mini) 
BisoproM 111 55.2 ,+ 12.34 51.5 ,+ 15.24 -3.6 (-23.5, 16.3) 0.0 0.284 
Nifedipine 112 118.8 ,+ 17.51 104.9 _+ 16.46 -13.9 (-39.2, 11.4) -4.0 0.151 
Mean HR before ST 
segment depression 
(beats/min) 
Bisoprolol 84.5 -- 1.68" 83.2 ,+ 1.73t -3.0 (-6.0, -0.1):~ -4.6 0.006 
Nifedipine 102.0 ,+ 1.23" 102.5 _+ 1.44t +0.7 (-2.0, 3.5):~ +0.3 0.460 
Number of patients (Pts) differs because heart rate (HR) at onset of ischemic episode is only applicable in those patients with episodes. *Bisoprolol (n = 69); 
nifedipine (n - 98). tBisoprolol (n = 53); nifedipine (n : 95). :~Bisoprolol (n = 44); nifedipine (n = 85). 
shown in Table 4. Patients were asked for their frequency of 
angina during the preceding week both at the start and end of 
the placebo phase and at the end of the low and high dose 
treatment phases. From 5.4 _ 0.56 and 5.7 +_ 0.59 attacks/ 
week, the number of anginal attacks was reduced to 2.8 _+ 0.47 
and 4.4 _+ 0.61 in the bisoprolol and nifedipine groups, 
respectively. For patients receiving the high dose, the weekly 
attacks were reduced from a baseline value of 5.8 _ 0.71 to 
2.3 _+ 0.41 with bisoprolol and from 5.7 _+ 0.65 to 3.2 + 0.48 
with nifedipine. Both drugs effectively reduced the frequency 
of angina pectoris. However, in individual patients the corre- 
lation of the number of anginal attacks per week and the 
number of ischemic episodes per 48 h was weak (for baseline 
and differences with treatments, r = 0.210 to 0.251). 
The time course of the number of weekly anginal attacks 
recorded at each visit is shown in Figure 2 for those patients 
who were eligible for both treatment phases. 
Effects on circadian variation of ischemia. Figure 3 shows 
the effects of bisoprolol and nifedipine on the circadian 
variation of transient ischemic episodes. During phase 1 of the 
study, the pronounced morning peak of episode frequency was 
markedly reduced with 10 mg of bisoprolol. With nifedipine 
slow release (2 x 20 mg), the circadian profile was unchanged 
but showed a clear overall reduction in the number of epi- 
sodes. The second peak of transient ischemic episodes during 
the late afternoon hours was more reduced with nifedipine 
than the morning peak. 
Responder rates. During both phases of the trial, the 
percent of patients who responded to treatment with a reduc- 
tion in episodes of transient ischemia was evaluated. Table 5 
shows the responder rates during phase 1 of the trial. For 
various definitions of response (between 25% and 100% 
reduction in the number of episodes), there was always a 
higher esponder rate for bisoprolol than for nifedipine. The 
difference was significant with the Fisher exact est and was 
similar for duration of episodes and total ischemic burden in a 
similar manner. During phase 2 of the trial there was some 
further increase in responder rates. The differences between 
bisoprolol and nifedipine remained significant: 52.5% of pa- 
tients achieved 100% reduction of transient ischemic episodes 
with bisoprolol versus only 15.6% of those with nifedipine. 
Adverse drug effects. One patient had an acute myocardial 
infarction after randomization to nifedipine but before ad- 
ministration of the first medication. During the study, 27 
patients taking bisoprolol and 29 taking nifedipine slow release 
had to be withdrawn from treatment: adverse vents in 20 
patients taking bisoprolol, 14 nifedipine; treatment failure in 
6 patients taking bisoprolol, 10 nifedipine; other problems in 1 
patient aking bisoprolol, 5 nifedipine. In most patients the 
adverse vent recorded was of cardiovascular o igin. Lack of 
effect on angina pectoris, occurrence oftachycardia and edema 
during nifedipine treatment and dyspnea nd bradycardia with 
bisoprolol therapy were the main problems observed. 
Discuss ion  
Prevalence of transient ischemia. Of 627 study patients 
who had a positive result on the exercise ECG, 330 had two or 
more transient ischemic episodes on 48-h ambulatory moni- 
toring, thus demonstrating the excellence of the exercise ECG 
in screening patients for studies of transient ischemia. How- 
ever, in our study, the exercise ECG was obtained in different 
centers throughout Europe after either a treadmill or a bicycle 
exercise protocol. Thus, comparison of a large number of 
exercise ECG results would have methodologic differences, 
and, therefore, centralized blinded evaluation of ambulatory 
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Figure 1. Effects of bisoprolol and nifedipine slow release (s,r.) on 
different measures of transient ischemic episodes (patients evaluable 
for phases 1 and 2: bisoprolol, n = 111; nifedipine, n = 112). Number, 
duration and total ischemic burden (mean ÷ SEM) are reduced 
significantly with both drugs. The difference in reduction between 
bisoproM and nifedipine is also significant (at least p = 0.01) for all 
variables compared. The doubling of the dose in phase 2 of the trial 
showed only a small incremental effect. 
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Figure 2. Number of anginal attacks per week (mean -2_ SEM) as 
recorded during the control visits of the patients (patients evaluable 
for phases 1 and 2). s.r. = slow release. 
ECG tapes was performed for objective documentation and 
comparison of anti-ischemic effects. The multicenter design of 
our study also allowed the inclusion of a sufficient number of 
patients to overcome methodologic problems with the variabil- 
ity of myocardial ischemia (19-21). The inclusion in our study 
of >50% of screened patients is a remarkably higher ate than 
that for other published studies. Fox et al. (22) reported 
transient ischemia in 16% of 409 patients creened for inclu- 
sion in the Regionally Organized Cardiac Key European Trial 
(ROCKET) study, and Parrnley et al. (23) included 207 of 
1,174 patients creened by 48-h ambulatory ECG monitoring 
for inclusion in a study on the effects of nifedipine gastroin- 
testinal therapeutic system (GITS). One reason may have been 
the higher prevalence of more severely diseased patients in the 
centers in Sweden, Poland and East Germany. 
Beta-blockade versus calcium antagonism. In our study 
the effects of the beta-blocker bisoprolol were greatly superior 
to those of the calcium antagonist nifedipine. Although both 
drugs showed significant treatment effects on both angina 
pectoris and transient ischemic episodes, the effects of biso- 
prolol were more marked at the dose levels tested. There is 
Table 4. Treatment Effect on Angina Pectoris 
Baseline Treatment 
No. of Anginal No. of Anginal 
Attacks/Week Mean _+ SEM Attacks/Week Mean _ SEM 
After 
Treatment 
(no. of anginal 
attacks/wk) 
Mean Change 
(mean [95% confidence limits]) 
Start of placebo 
Bisoprolol 159 5.9 _+ 0.52 
Nifedipine 163 6.0 _+ 0.51 
Low dose 
Bisoprolol 143 5.4 _+ 0.56 
Nifedipine 147 5.7 -+ 0.59 
High dose 
Bisoprolol 125 5.8 + 0.71 
Nifedipine 129 5.7 _+ 0.65 
136 
140 
120 
125 
2.8 -+ 0.47 
4.4 -+ 0.61 
2.3 -+ 0.41 
3.2 + 0.48 
136 
140 
120 
125 
-2.6 (-1.5, -3.7)* 
-1.2 (0.1, -2.5) 
-3.0 (-2.3, -3.8)* 
-2.3 (-1.1, -3.6)* 
*Significant reduction; confidence limits do not include zero. 
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Figure 3. Effect of bisoprolol and nifedipine on the circadian distri- 
bution of transient ischcmic episodes (sum of episodes/h on two 
consecutive days as mean value/patient; patients evaluable for phases 
1 and 2: bisoprolol, n - 111, nifcdipine, n - 112). From comparable 
baseline curves, bisoprolol effectively reduces the morning and after- 
noon peaks of transient ischcmic episodes, whereas nifedipine reduces 
the overall number of episodes but leaves the circadian distribution 
unchanged, s.r. = slow release. 
ongoing discussion about the importance of increased emand 
versus reduced supply in the pathophysiology of ambulatory 
myocardial ischemia (24). The results obtained in our large 
patient groups would certainly favor a primary role for in- 
creased demand as the trigger for ambulatory myocardial 
ischemia. Increases in heart rate have often been shown to be 
the main determinants of ambulatory silent ischemia (25-30), 
but there may be a subset of patients who respond differently 
(31), in particular to such triggers as mental stress (32-34). 
Furthermore the threshold at which ischemia occurs may 
vary (21). In our study bisoprolol not only reduced markedly 
the number and duration of transient ischemic episodes, but 
also reduced the heart rate at which ischcmic episodes oc- 
curred. 
We compared the effects of bisoprolol with those of the 
widely used calcium antagonist nifedipine in the available 
formulation at the start of the study. It is conceivable that 
nifedipine in a newer formulation, the gastrointestinal thera- 
peutic system (GITS) used in the study by Parmley et al. (23), 
might have produced more favorable results. A reduction in 
the episodes of transient ischemia has been shown for dilti- 
azem (35), a calcium antagonist that reduces heart rate, and for 
amlodipine (36), a calcium antagonist with a long half-life. 
However, in both studies the reduction in episodes was --50% 
of the baseline value, which is less than the 60%-70% achieved 
with bisoprolol in our study. A detrimental effect of nifedipine 
may be induced in some patients with collateral flow, as 
Egstrup and Andersen (37) have shown. In their patient group 
with good collateral flow, nifedipine administration was fol- 
lowed by an increase in total and silent ischemia. Smaller 
studies (38-40) have shown conflicting results with nifedipine 
and other calcium antagonists compared with, or in addition 
to, beta-blockers. In a recent study (41) comparing diltiazem 
and atenolol in patients with variable-threshold angina, there 
was a greater eduction of ischemic episodes with diltiazem 
than with atenolol. 
Open question: prognosis. Because angina pectoris is not 
treated only for pain relief but also in the hope that effective 
treatment of angina will reduce dangerous equelae, such as 
myocardial infarction and sudden death, transient, predomi- 
nantly silent ischemia is also treated on the basis of prognosis. 
However, the medical treatment of silent ischemia is not 
uniformly accepted (42-46). The solution of this problem must 
await larger studies that show that treatment of silent ischemia 
can in fact improve the prognostic outcome of patients. Initial 
results point in that direction: Lim et al. (47) showed that in 
patients with painless ischemia that was abolished by medical 
treatment, he prognosis was significantly better than in those 
with painless ischemia, as detected with radionuclide ventricu- 
lography, that persisted despite treatment. Raby et al. (48) 
showed a higher event rate in patients with transient ST 
segment depression on ambulatory ECG monitoring that 
persisted during medical therapy. Suppression of silent isch- 
emia by beta-blockade may not be all that is needed to improve 
prognosis because it has been shown (49) that the morning 
increase in platelet aggregability remains unchanged in pa- 
tients with coronary artery disease in whom the morning peak 
of transient ischemic episodes was reduced. 
Conclusions. This large multicenter study included se- 
lected patients with stable angina pectoris, a positive result on 
the exercise ECG and evidence of transient ischemia on 
ambulatory ECG monitoring. Bisoprolol in a single daily dose 
was an effective antianginal and anti-ischemic treatment. In the 
reduction of the number and duration of ischemic episodes 
Table 5. Rcsponder Rates 
Low Dose 
Bisoprolol Nifedipine 
Reduction i No. (1 × 10 rag) (2 × 20 mg s.r.) p Value 
of Episodes (n - 133) (n - 135) (bisoprolol vs. nifcdipine) 
High Dose 
Bisoprolol Nifedipine 
(1 x 20 rng) (2 × 40 mg s.r.) p Value 
(n - 118) (n - 122) (bisoprolol vs. nifedipine) 
->255'~ 114 (85.7';4) 80 (59.3%) >0.0001 105 (89.0%) 76 (62.3%) <0.0001 
->50% 98 (73.75~) 57 (42.4%) >0.0001 95 (80.5%) 60 (49.2%) <0.0001 
>75% 75 (56.49~) 31 (23.0%) <0.0001 80 (67.8%) 40 (32.8%) <0.0001 
100% 54 (41).691) 20 (14.8%) <0.0001 62 (52.5%) 19 (15.6%) <0.0001 
Data presented are number (~:'}) of responders, s.r. slow release. 
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and total ischemic burden, bisoprolol proved superior to 
nifedipine, which also showed significant reatment effects. 
Bisoprolol was also superior to nifedipine with regard to 
responder rates and effect on angina and on the circadian 
variation of ischemic episodes. Thus, in a large group of 
patients with stable coronary artery disease, the main determi- 
nant of transient myocardial ischemia seems to be increased 
oxygen demand, which can be reduced by reducing heart rate 
with a beta-blocker. The question of whether the observed 
marked treatment effects on transient myocardial ischemia 
translate into an improved prognosis for the patients must 
await the results of larger prospective studies. 
Appendix 
Participating Institutions and Personnel for the 
Total Ischemic Burden Bisoprolol Study 
Principal investigator. T. yon Arnim, Mtinchen, Germany. Board of investi- 
gators. T. yon Arnim, Mimchen, H. Duck, Leipzig, H. O. Morgenstern, Darm- 
stadt, W. Teichmann, Halle, Germany; L. Relik-van Wely, Eindhoven, The 
Netherlands; D. Sagastagoitia, Bilbao, Spain; S. Swiatecka, Gdansk, Poland; A. 
Terent, Sbderhamn, Sweden. 
Clinical centers. Belgium: R. Popeye, Veume. Germany: I Al3mann, A. Lang, 
Erfurt; R. Bohm, Berlin; H. Duck, Leipzig; H. D. Faulhaber, J. Enderlein, 
Berlin-Buch; H. Giilker, H. Probst, H. Teutemacher, Wuppertal; H. Schaedel, Bad 
Berka; J. Schauer, L. Steininger, G. Wolff, Leipzig; W. Teichmann, E. Brix, J. 
Scholz, Halle; W. Urbaszek, J. Kram, F. Weber, Rostock. Italy: S. Caponetto, 
Genova; C. Mazzola, G. Serra, Casatenovo. The Netherlands: R. Ciampricotti, 
Temeuzen; M. C. Huige, Veldhoven; L. Relik-van Wely, Eindhoven; H. 
Roozendaal, Utrecht. Poland: A. Cieslinski, R. Ochotny, P. Mitkowski, Poznan; J.
Grezlikowski, W. Krasowski, B. Krupa-Wojciechowska, A. Rynkiewicz, 
K. Leonowicz, J. Siebert, D. Ciecwierz, S. Swiatecka, E. Krzyminska, Gdansk; A. 
Kalicinski, A. Korecki, A. Poniatowski, Bialystok; E. Nartowicz, A. Grabczewska, 
Bydgoszcz; Z. Sadowski, W. Luczak, S. Jasek, Warsawa. Spain: E. Marin, I. 
Rayo, C. Moro, Madrid; D. Sagastagoitia, E. Molinero, M. Iriarte, Bilbao. 
Sweden: O. Fredholm, Ljungby; B. Svanstroem, Kristianstad; A. Terent, SOder- 
hamn; G. Ulvenstam, Gdteborg. 
Central ttolter tape evaluation. J. E. Deanfield, London, England, United 
Kingdom. Coordination. H. O. Morgenstern, M. Schulte, Darmstadt, German),. 
Local monitoring. F. Moerkerke, Overijse. Belgium; M. Schulte, P. Pollert, 
Darmstadt, German),; R. Chiecca, G. Rivolta, Milano, Italy; R. van Herwaarden, 
Amsterdam, The Netherlands; E. Krzyminska, Gdansk, Poland; J. Carretero, 
Mollet des Valles, Spain; R. Dahlstr6m, Stockholm, Sweden. Data management. 
A. Neumann, Bechtolsheim, P. Pollert, Darmstadt, German),. Statistics. H. 
Wiemann, C. Niemeyer, Darmstadt, Germany. 
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